Predicting early response to ablative radiotherapy in oligometastatic disease: a scoping review of radiomics-based machine learning and deep learning models - Report - MDSpire
Advertisement
Predicting early response to ablative radiotherapy in oligometastatic disease: a scoping review of radiomics-based machine learning and deep learning models
Clinical Report: Assessing Early Treatment Response to Ablative Radiotherapy in Oligometastatic Cancer
Overview
This comprehensive review evaluates the predictive performance of machine learning and deep learning models using radiomic data to assess early treatment response in oligometastatic cancer patients treated with ablative radiotherapy. It highlights the need for standardized methodologies to enhance the clinical applicability of these predictive models.
Background
Oligometastatic disease (OMD) represents a critical stage in cancer progression, where patients may benefit from aggressive local treatments like ablative radiotherapy (ART). Despite advancements in ART, failure rates remain significant, necessitating improved methods for predicting treatment response. Radiomics and machine learning offer promising avenues for capturing tumor characteristics and enhancing treatment decision-making.
Data Highlights
No specific numerical data or trial results were provided in the article.
Key Findings
Oligometastatic disease is defined by the presence of one to five metastases, typically treatable with local therapies.
Ablative radiotherapy (ART) is a key treatment modality for OMD, with significant failure rates observed.
Radiomics can extract quantitative imaging features that may serve as biomarkers for tumor biology.
Machine learning and deep learning techniques can analyze radiomic data to predict treatment outcomes.
Current studies on ML and DL models are limited by methodological heterogeneity and single-center designs.
Standardized reporting and methodological quality assessments are essential for enhancing the robustness of radiomic studies.
Clinical Implications
Healthcare professionals should consider integrating radiomic and machine learning approaches into clinical practice to better predict treatment responses in oligometastatic cancer patients. Standardization of methodologies and reporting will be crucial for the broader applicability of these predictive models in clinical settings.
Conclusion
The integration of radiomics and machine learning in assessing early treatment response in oligometastatic cancer presents a promising frontier in personalized medicine. Continued research and standardization are necessary to fully realize the potential of these technologies.
by Raquel García-Pablo, Marta Canela-Capdevila, Alberto Martínez-Caballero, Rocío Benavides-Villareal, Albert Moragas-Fernández, Andrea Jiménez-Franco, Berta Piqué-Smith, Camila Montesinos-Guevara, Jordi Camps, Jorge Joven, Angel Torrado-Carvajal, Meritxell Arenas
